

Figures 1A-D




Figure 2A




Figure 2B




Figure 2C




Figure 2D




Figure 3




Figure 4A




Figure 4B




Figure 4C





Figure 5



Figures 6A-B




Figure 7






Figure 8A

Figure 8B





PFA 100 Closure time (measures ability to clot) is increased by the PPARγ Agonist Rosiglitazone (Avandia)





Figure 9



PFA-100 Closure
Times employing
ADP cartridge and
15 minute
incubations of
platelets with DMSO
vehicle or 20µM
15dPGJ2

- □ DMSO mean=80±14
- J2 mean = 87 ± 17

p=0.012 by two tailed paired t

Figure 10







Figure 11

PPARy Western Blots







hUrine Pt.17 (50 μg)




Figure 12A

*Scale of - to ++++

PPARy Protein Levels in Human and Mouse Tissues and Fluids

	_
Human Adipocyte	++
Human Platelet	·
Human Orbital Tissue	++++
Human Colostrum	++-+-
Human Tears	- to +/ -
Human Cerebrospinal Fluid	+++
Human Peritoneal Fluid	+++
Human Saliva	+
Human Sweat	_
Human Serum	++++
Human Plasma	+++
Human Urine	- to +++
Mouse Serum	+-+-+-
Mouse Plasma	++++
Mouse Urine	_

Figure 12B




Figure 13




Figure 14